Drinking, Acetate, and Stress Study

This study aims to understand how drinking alcohol affects your stress levels and body chemistry. Researchers will use a special imaging method called Deuterium Metabolic Imaging (DMI) with a tracer called deuterated acetate. This helps them see how your brain uses acetate, which is related to brain chemicals like glutamate and glutamine (Glx). They will also measure your stress hormone levels (cortisol) and how much you drink. The study is looking for 50 participants between 18 and 55 years old who meet the criteria for Alcohol Use Disorder (AUD). Success would mean finding better ways to help people reduce or stop harmful drinking. The current status of the study is unclear.

Study design
This is an interventional study planning to enroll 50 participants. The phase of the study is not specified.
What's involved
You would receive deuterated acetate intravenously over two hours while undergoing Magnetic Resonance Spectroscopy (MRS) and structural Magnetic Resonance Imaging (MRI). You will also complete self-assessments and have your blood drawn for cortisol levels. For those seeking treatment, these measurements will be taken at baseline, once within about a week, and again after approximately one month of sobriety.
Compensation
Not stated in the trial record.
Follow-up
For treatment seekers, brain chemical measurements will be taken at baseline and again after 1 month sober.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06584448

Drinking, Acetate, and Stress

Recruiting
NAAges 18–60InterventionalBasic science
Yale University
~50 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:Deuterium Metabolic Imaging with deuterated acetate tracer

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of Conversion of Acetate to Glutamate + Glutamine (Glx) in the Brain
Measured over Baseline and for TS, once within approximately one week and again at approximately one month
+1 more outcome measured
Alcohol Use Disorder
Alcohol Use, Unspecified
Heavy Drinker
Alcohol Use Disorder, Moderate, in Sustained Remission
2 sites across 1 states
Connecticut2
  • Graeme Mason, Ph.D. · PRINCIPAL_INVESTIGATOR · Yale University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Medically stable male or female, aged 18-55.
Able to read, write and complete a multitude of self-assessments in English
Meets DSM-5 criteria for current Alcohol Use Disorder (AUD)
Participants who have Alcohol Use Disorder and are actively drinking must be willing to receive (at no cost) inpatient treatment for AUD for a period of up to 30 days. Participants who have been treated for an Alcohol Use Disorder and are now sober three months or longer will NOT be required to go inpatient.

Exclusion

Subjects with any significant current medical conditions (neurological, cardiovascular, endocrine, thyroid, renal, liver), seizures (for LTS subjects only- seizures directly related to alcohol detoxification are not an exclusion) , delirium or hallucinations, or other unstable medical conditions, including HIV.
Current DSM-5 substance use disorder (other than AUD or tobacco use disorder)
Any metallic objects implanted in their body which would make imaging unsafe (pacemaker, etc)
Claustrophobia, or other inability to participate in an MRI
A positive test result at intake appointment and subsequent appointments on urine drug screens conducted for illicit drugs. (Note: participants will not be paid for study visits if they test positive for an illicit drug and will be immediately excluded from study).
Women who are pregnant or nursing. Women who have an IUD that would make imaging unsafe.
Recent taking of medications that may influence study outcomes (e.g., disulfiram, naltrexone, acamprosate, anticonvulsants).
Subjects likely to exhibit clinically significant alcohol withdrawal during the study.
  • Rate of Conversion of Acetate to Glutamate + Glutamine (Glx) in the BrainBaseline and for TS, once within approximately one week and again at approximately one month

    DMI data will be acquired during infusions of 2H-labeled Ac, using a 4-Tesla magnet. Deuterium flow from \[2,2,2-2H3\]Ac to glutamate (Glu) and glutamine (Gln). Ac forms AcetylCoA at a rate CMRAc and is oxidized by astroglia (VtcaA), labeling the small glial Glu pool (5-10% of the total Glu110).Astroglial Glu is converted to Gln and sent to neurons (Vcycle), where it is converted to labeled Glu. It mixes with the large neuronal Glu pool, fed also by unlabeled carbon mostly from glucose via neuronal oxidation (VtcaN), and the diluted Glu is released and taken up by glia for reconversion to Gln. With 2H, the sum of Glu and Gln is detected as \[2H\]Glx. The faster the rate of acetate consumption, the faster the appearance of \[2H\]Glx.

  • Concentration of [2H]Glx in the brain during administration of [2H]acetateBaseline and for treatment seekers, once after 1 month sober.

    DMI data will be acquired during infusions of 2H-labeled Ac, using a 4-Tesla magnet. Deuterium flow from \[2,2,2-2H3\]Ac to glutamate (Glu) and glutamine (Gln). Ac forms AcetylCoA at a rate CMRAc and is oxidized by astroglia (VtcaA), labeling the small glial Glu pool (5-10% of the total Glu110).Astroglial Glu is converted to Gln and sent to neurons (Vcycle), where it is converted to labeled Glu. It mixes with the large neuronal Glu pool, fed also by unlabeled carbon mostly from glucose via neuronal oxidation (VtcaN), and the diluted Glu is released and taken up by glia for reconversion to Gln. With 2H, the sum of Glu and Gln is detected as \[2H\]Glx. The faster the rate of acetate consumption, the faster the appearance of \[2H\]Glx.